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Abstract
Background: Paediatric data on the association between diagnostic delay and inflammatory bowel
disease [IBD] complications are lacking. We aimed to determine the effect of diagnostic delay on
stricturing/fistulising complications, surgery, and growth impairment in a large paediatric cohort,
and to identify predictors of diagnostic delay.
Methods: We conducted a national, prospective, multicentre IBD inception cohort study including
1399 children. Diagnostic delay was defined as time from symptom onset to diagnosis >75th
percentile. Multivariable proportional hazards [PH] regression was used to examine the association
between diagnostic delay and stricturing/fistulising complications and surgery, and multivariable
linear regression to examine the association between diagnostic delay and growth. Predictors of
diagnostic delay were identified using Cox PH regression.
Results: Overall (64% Crohn’s disease [CD]; 36% ulcerative colitis/IBD unclassified [UC/IBD-U];
57% male]), median time to diagnosis was 4.2 (interquartile range [IQR] 2.0–9.2) months. For
the overall cohort, diagnostic delay was >9.2 months; in CD, >10.8 months and in UC/IBD-U,
>6.6 months. In CD, diagnostic delay was associated with a 2.5-fold higher rate of strictures/internal
fistulae (hazard ratio [HR] 2.53, 95% confidence interval [CI] 1.41–4.56). Every additional month
of diagnostic delay was associated with a decrease in height-for-age z-score of 0.013 standard
© The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation.
All rights reserved. For permissions, please email: journals.permissions@oup.com
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deviations [95% CI 0.005–0.021]. Associations persisted after adjusting for disease location and
therapy. No independent association was observed between diagnostic delay and surgery in CD
or UC/IBD-U. Diagnostic delay was more common in CD, particularly small bowel CD. Abdominal
pain, including isolated abdominal pain in CD, was associated with diagnostic delay.
Conclusions: Diagnostic delay represents a risk factor for stricturing/internal fistulising
complications and growth impairment in paediatric CD.
Podcast: This article has an associated podcast which can be accessed at https://academic.oup.com/ecco-jcc/pages/podcast
Key Words: Inflammatory bowel disease [IBD]; fistula; stricture

1. Introduction

2. Materials and Methods
2.1. Study design and participants
The Canadian Children IBD Network [CIDsCaNN], a joint partnership with the Canadian Institutes of Health Research [CIHR] and the
CH.I.L.D. Foundation, maintains a prospective, national, paediatric
IBD inception cohort study. Children <17 years of age, newly diagnosed with IBD at participating paediatric academic centres across
Canada, are enrolled at time of diagnosis and followed until the current
date or transition to adult care [at 18 years of age]. Data are collected
prospectively at each clinic visit using standardised case report forms
and are entered into a research electronic data capture [REDCap]
database, with central oversight provided by the data coordinating
centre. Standard diagnostic work-up at participating centres includes
upper endoscopy and ileocolonoscopy, as well as small bowel imaging
with magnetic resonance enterography [MRE] in CD. Disease location is defined according to the paediatric Paris modification of the

2.2. Variables and outcomes
The following baseline factors were extracted for analysis: date
of symptom onset [date ‘last well’], date of IBD diagnosis [diagnostic ileocolonoscopy], IBD type, age at diagnosis, sex, presenting
gastrointestinal and extraintestinal symptoms and signs [outlined in
Tables 1 and 2], disease location and behaviour, height for age z-scores
[HAZ], weight for age z-scores [WAZ], clinical (weighted Paediatric
CD Activity Index [wPCDAI] in CD, Paediatric UC Activity Index
[PUCAI] in UC) and, endoscopic activity (Simple Endoscopic Score-CD
[SES-CD] in CD, Mayo endoscopic sub-score in UC), serum markers
(C-reactive protein [CRP], erythrocyte sedimentation rate [ESR], albumin), initial induction and maintenance therapy, and family history
of IBD [first-degree relative]. Dates of subsequent clinical outcomes of
interest, namely surgery and stricturing and/or internal fistulising complications in CD, were extracted as well. As previously described,11 clinical site directors, all paediatric gastroenterologists with a clinical focus
in IBD, were responsible for approving IBD diagnostic labels as CD
or UC as per standard clinical, endoscopic, and histological criteria.
In CIDsCaNN, the designation of IBD-U [with the option to specify
whether favouring CD or UC] is applied in the setting of colonic IBD
with features suggestive of both UC and CD, anticipating that a clearer
impression of CD or UC may be verified over time.
Time to diagnosis was defined as the interval between symptom
onset [date ‘last well’] and diagnostic ileocolonoscopy. A prolonged
time to diagnosis [‘diagnostic delay’] was defined as a time to diagnosis greater than the 75th percentile, as has been done previously
[for subgroup analyses, the CD- and UC/IBD-U specific definitions
of diagnostic delay were used].6,12,13 For the primary analyses, patients with IBD-U favouring CD were grouped with CD, and patients
with IBD-U favouring UC and IBD-U were grouped with UC. In
addition, we undertook analyses specific to the IBD-U population
[including IBD-U, IBD-U favouring UC, and IBD-U favouring CD],
presented in Supplementary materials, available as Supplementary
data at ECCO-JCC online.

2.3. Statistical analysis
Continuous variables were summarised as medians with interquartile
range [IQR] and categorical variables as frequencies with proportions. Patient and disease characteristics were compared between patients with and without diagnostic delay [separately for CD and UC],
using the Mann‐Whitney U test for continuous variables and the chi
square test for categorical variables [or Fisher’s exact test where less
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Canada has one of the highest rates of inflammatory bowel disease
[IBD] in the world.1 It is projected that by the year 2030, the prevalence
of IBD in Canada will approach 1% [981 per 100 000].2 About a fifth
of IBD cases have their onset in the paediatric age range,3 and children
are the patient subgroup predicted to experience the largest annual percentage increase in IBD prevalence over the coming decade.2 As these
patients will live with IBD for their full lives, optimising their management and outcomes has critical implications for individual quality
of life and health care costs. Furthermore, it has been shown that the
period preceding IBD diagnosis is associated with increased societal
costs,4 providing additional incentive to expedite IBD diagnosis.
In adults, several studies support an association between diagnostic delay and an increased risk of disease complications, particularly in Crohn’s disease [CD]. Such complications include stenosis,
internal fistulae, and surgery.5–9 However, paediatric data on the topic
of diagnostic delay, and particularly its association with disease complications, remain sparse. In a recent study using data from the Swiss
IBD Cohort Study, children with diagnostic delay were not at increased
risk of stricturing or fistulising complications or surgical resection over
time. This was in contrast to the adults in this cohort.8 The reasons
for the discrepancy between this paediatric population and the adult
literature are unclear; they may relate to differences in sample size,
follow-up duration, or the way in which diagnostic delay was defined.
Given the importance of diagnostic delay as a potentially actionable factor for optimising paediatric IBD outcomes, we aimed
to characterise time to diagnosis and its predictors in a large, prospective, national, paediatric IBD inception cohort and to examine
the relationship between diagnostic delay and clinically important
outcomes, including stricturing and fistulising complications,
growth, and surgery.

Montreal classification.10 At the baseline visit, data are systematically
collected about presenting symptoms and signs with corresponding
dates of onset. Patients and families are specifically questioned by
treating physicians during interview about the date patients were ‘last
well’, which is recorded. Children enrolled between January 2014 and
January 2019 were included in this analysis.

Diagnostic Delay in Paediatric IBD

421

Table 1. Patient and disease characteristics at diagnosis, overall and by diagnostic delay status [<75th percentile vs >75th percentile], CD
subgroup.
N [%] or median [IQR]

Overall
[N = 898]

Without diagnostic delay
[N = 674]

p-value

132 [59%]
13.2 [10.9–14.8]
36 [16%]

408 [61%]
12.8 [10.7–14.8]
113 [17%]

0.67
0.48
0.81

53 [26%]
59 [28%]
26 [13%]
69 [33%]
177 [86%]
46 [22%]
55 [27%]
15 [7%]
25 [13%]
30 [15%]
19 [10%]
47 [24%]
12 [6%]
109 [55%]
104 [53%]

116 [18%]
202 [31%]
62 [9%]
277 [42%]
575 [88%]
94 [14%]
187 [29%]
42 [6%]
186 [30%]
146 [24%]
61 [10%]
172 [28%]
28 [5%]
376 [61%]
292 [48%]

0.45
0.007
0.60
0.67
<0.001
0.011
0.89
0.24
0.40
0.13
0.21

35 [17%]
29 [14%]
8 [4%]
17 [8%]

96 [16%]
93 [15%]
28 [4%]
49 [8%]

0.69
0.72
0.69
0.88

0.019

-0.31 [-1.20-0.41]
-0.76 [-1.75-0.36]
70 [36%]
121 [61%]

-0.09 [-0.75-0.65]
-0.57 [-1.43-0.30]
101 [16%]
468 [76%]

0.002
0.08
<0.001
<0.001

2.2 [1.0–4.7]
27 [15–44]
36 [33–40]

3.2 [1.2–7.1]
38 [22–56]
34 [29–39]

0.03
<0.001
<0.001

42 [25–62]

58 [38–78]

<0.001
<0.001

9 [4%]
76 [34%]
99 [45%]
37 [17%]

14 [2%]
143 [22%]
312 [47%]
196 [29%]

10 [5%]
53 [25%]
55 [26%]
95 [44%]
130 [64%]
64 [29%]
157 [74%]

21 [3%]
105 [17%]
174 [27%]
337 [53%]
386 [66%]
127 [20%]
463 [72%]

0.74c
0.002
0.72

199 [89%]
16 [7%]
4 [2%]
4 [2%]
24 [11%]
13 [6.5–19]

604 [92%]
42 [6%]
3 [0.5%]
9 [1%]
54 [8%]
16 [9–23]

0.21
<0.001

73 [11%]

0.12

0.027b

16 [7%]
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Patient demographics
Male
540 [60%]
Age at diagnosis [years]
12.9 [10.8–14.8]
Family history of IBD
149 [17%]
Presenting symptoms and signs
Stool type
Formed, non-bloody
169 [20%]
Non-bloody diarrhoea
261 [30%]
Formed, bloody
88 [10%]
Bloody diarrhoea
346 [40%
Abdominal pain
752 [87%]
Isolated abdominal pain
140 [16%]
Perianal symptoms
242 [28%]
Isolated perianal symptoms
57 [7%]
Fever
211 [26%]
Vomiting
176 [22%]
Skin manifestations
80 [10%]
Oral ulcers
219 [27%]
Arthritis
40 [5%]
Anaemia
485 [60%]
Iron deficiency
396 [49%]
Extraluminal manifestations at presentation [as per physician assessment]
Perianal disease
131 [16%]
Any extraintestinal manifestations
122 [15%]
Skin involvement
36 [4%]
Joint involvement
66 [8%]
Anthropometrics at presentation
Height for age z-score
-0.14 [-0.93-0.59]
Weight for age z-score
-0.63 [-1.50-0.30]
Reported linear growth impairment
171 [21%]
Reported weight loss
589 [73%]
Biochemistry at presentation
CRP [x upper limit of normal]
3.0 [1.2–6.6]
ESR [mm/h]
36 [20–52]
Albumin [g/L]
35 [30–39]
Disease characteristics at presentation
wPCDAI
55 [35–75]
Physician global assessment
None
23 [3%]
Mild
219 [25%]
Moderate
411 [46%]
Severe
233 [26%]
Location [Paris classification]
No L1-L3 macroscopic involvement
31 [4%]
L1
158 [18%]
L2
229 [27%]
L3
432 [51%]
L4
516 [65%]
Isolated small bowel disease [L1 ± L4 or L4]
191 [22%]
Small bowel disease [±colonic]
620 [73%]
[L1, L3 or L4b]
Disease behaviour
B1 [inflammatory]
803 [91%]
B2 [stricturing]
58 [7%]
B3 [internal fistulising]
7 [0.8%]
B2B3
13 [1%]
B2 and/or B3
78 [9%]
Simple endoscopic score-CD [SES-CD]
15 [9–21]
Medical therapy
Induction
5ASA/sulphasalazine
89 [10%]

With diagnostic delaya
[N = 224]
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Table 1. Continued
N [%] or median [IQR]
Systemic steroids
Exclusive enteral nutrition
Anti-TNF
Methotrexate
Antibiotics
Rectal therapy alone
Dietary modifications
Surgery
None

Overall
[N = 898]
276 [31%]
324 [36%]
146 [16%]
20 [2%]
22 [2%]
1 [0.1%]
3 [0.3%]
2 [0.2%]
13 [1%]

With diagnostic delaya
[N = 224]

Without diagnostic delay
[N = 674]

p-value

54 [24%]
102 [46%]
31 [14%]
6 [3%]
7 [3%]
0
2 [1%]
0
4 [2%]

222 [33%]
222 [33%]
115 [17%]
14 [2%]
15 [2%]
1 [0.2%]
1 [0.2%]
2 [0.3%]
9 [1%]

0.016
<0.001
0.28
0.60
0.44
1.0
0.15
1.0
0.75

than five cell counts were expected]. The association between diagnostic delay and the development of stricturing/internal fistulising
complications following diagnosis [in CD] and surgery [in CD and
UC] was examined using univariate and multivariable [MVA] Cox
proportional hazards [PH] regression [with date of diagnosis set as
time zero]. The analysis of stricturing/fistulising complications was
restricted to patients without complications [ie, with an inflammatory
phenotype] at diagnosis. The association between time to diagnosis
and HAZ at presentation was examined using univariate and MVA
linear regression. Finally, IBD-related presenting symptoms and signs
were tested for their relationship with time to diagnosis [in an attempt to identify predictors of diagnostic delay] using univariate and
MVA Cox PH regression. In all cases, the variables included in MVA
models were selected a priori based on clinical relevance. Results
were expressed as unadjusted and adjusted hazard ratios [HRs] or
beta coefficients, as appropriate, with 95% confidence intervals [CI].
Given the importance of disease location as a potential confounder,
in addition to MVA analyses, sensitivity analyses restricted to patients
with small bowel involvement were performed for the outcomes of
stricturing/fistulising disease and growth.
Statistical significance was defined as a p-value <0.05. All statistical analyses were performed using SAS University Edition [version
3.4, SAS Institute, Cary, NC].

2.4. Ethics
The study was approved by the institutional ethics review board at
each participating centre. Informed consent was obtained from all
individual participants included in the cohort and their parents/legal
guardians.

3. Results
Between January 2014 and January 2019, 1399 children were enrolled in the inception cohort and included in the analysis. Diagnostic
labels included 881 [63%] CD, 435 [31%] UC, and 83 [6%] IBD-U
[including 17 IBD-U favouring CD and 39 IBD-U favouring UC].
As outlined above, for subsequent analyses, UC and IBD-U were
grouped together [N = 501], except for IBD-U favouring CD, which
was grouped with CD [N = 898]. The median age at IBD diagnosis
was 13.0 [10.7–15.0] years. The median follow-up duration was 2.7
[IQR 1.7–3.6] years; follow-up duration was similar in patients with
and without diagnostic delay.

3.1. Baseline patient and disease characteristics
The median time from symptom onset to diagnosis for the overall
cohort was 4.2 [2.0–9.2] months, with 19% of patients diagnosed
more than 1 year after symptom onset. The median time to diagnosis was significantly longer in CD [4.9, IQR 2.3–10.8, months]
than UC/IBD-U [3.1, IQR 1.5–6.6, months] [p <0.001]. The distribution of times to diagnosis for CD and UC/IBD-U is shown in
Supplementary Figure 1, available as Supplementary data at ECCOJCC online; 23% of CD patients were diagnosed more than 1 year
after symptom onset, compared with 12% of UC/IBD-U patients
[p <0.001]. Even after adjusting for patient age, sex, colonic involvement, and clinical activity at presentation, CD remained independently associated with a slower rate of diagnosis, compared with UC/
IBD-U [HR 0.72, 95% CI 0.64–0.81, Supplementary Table 1, available as Supplementary data at ECCO-JCC online]. The median time
to diagnosis in the 83 children with an IBD-U label was 4 [IQR
1.8–9.4] months, intermediate between CD and UC.
Differences in presenting symptoms and signs, disease characteristics, and therapy between patients with and without diagnostic delay are highlighted in Tables 1 and 2, for CD and UC/
IBD-U, respectively. In both groups, bloody diarrhoea and more
active disease, clinically [based on wPCDAI and PUCAI] and
endoscopically, were associated with a faster diagnosis; in UC/
IBD-U, patients with PUCAI ≥65 at presentation [severe colitis]
had a shorter time to diagnosis [median 2, IQR 1–4.5, months]
than those with PUCAI < 65 [median 4, IQR 2–7.6, months]
[p <0.001]. In CD, isolated abdominal pain [without intestinal
symptoms] was associated with a slower diagnosis. Disease location differed according to diagnostic delay status, with more
isolated small bowel disease [in CD] and more limited, left-sided
disease [in UC/IBD-U] in the diagnostic delay group. In both
groups, no association was observed between diagnostic delay
and any of age, sex, family history of IBD, or extraintestinal skin/
joint/eye symptoms.
At presentation, there was no difference in the proportion of
CD patients with complicated luminal disease [strictures or internal fistulae] between patients with and without diagnostic delay.
In CD [but not UC], HAZ was lower at presentation in patients
with delayed diagnosis; CD patients with linear growth impairment
were more likely to have small bowel involvement [80% vs 73%,
p = 0.044] and distal small bowel disease [L4b] specifically [26% vs
17%, p = 0.011].
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IBD, inflammatory bowel disease; CD, Crohn’s disease; IQR, interquartile range; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; wPCDAI,
weighted Paediatric Crohn’s Disease Activity Index; SES-CD, Simple Endoscopic Score; 5-ASA, 5-aminosalicylate; TNF, tumour necrosis factor.
a
Time to diagnosis >75th percentile in CD subgroup [10.8 months].
b
Overall comparison of all categories.
c
Comparison of L4.
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Table 2. Patient and disease characteristics at diagnosis, overall and by diagnostic delay status [<75th percentile vs. >75th percentile], UC/
IBD-U subgroup.
N [%] or median [IQR]

Overall
[N = 501]

With diagnostic delaya
[N = 124]

189 [50%]
13.1 [10.0–15.4]
63 [17%]

p-value

0.77
0.28
0.56
<0.001

2 [0.5%]
13 [3.5%]
21 [6%]
338 [90%]
310 [83%]
2 [0.5%]
37 [12%]
58 [18%]
9 [3%]
28 [9%]
3 [1%]
189 [60%]
159 [50%]

0.44
0.26
0.027
0.50
0.33
0.33
0.057
0.66
0.041

29 [8%]
4 [1%]
6 [2%]

0.27
0.58
0.26

0.19 [-0.50–0.82]
-0.04 [-0.79-0.72]
10 [3%]
222 [70%]

0.56
0.50
0.36
<0.001

0.7 [0.2–1.9]
26 [14–44]
37 [32–41]

0.11
0.008
<0.001

55 [40–70]

<0.001
<0.001

11 [3%]
70 [19%]
150 [41%]
137 [37%]
0.071b
6 [2%]
27 [7%]
20 [5%]
43 [12%]
270 [74%]
313 [86%]
2 [2–3]

0.009c
0.006d
0.018

111 [30%]
250 [67%]
4 [1%]
6 [2%]
2 [0.5%]

<0.001
<0.001
0.37
0.009
1.0

IBD, inflammatory bowel disease; CD, Crohn’s disease; IQR, interquartile range; UC/IBDU, ulcerative colitis, inflammatory bowel disease unclassified; PUCAI,
Paediatric Ulcerative Colitis Activity Index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; 5-ASA, 5-aminosalicylate; TNF, tumour necrosis factor.
a
Time to diagnosis >75th percentile in UC/IBD-U subgroup [6.6 months].
b
Overall comparison of all categories.
c
Comparison of E4.
d
Comparison of E3-E4.
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Patient demographics
Male
253 [50%]
64 [52%]
Age at diagnosis [years]
13.2 [10.4–15.5]
13.4 [11.2–15.6]
Family history of IBD
81 [16%]
18 [15%]
Presenting symptoms and signs
Stool type
Formed, non-bloody
4 [1%]
2 [2%]
Non-bloody diarrhoea
25 [5%]
12 [10%]
Formed, bloody
42 [8%]
21 [17%]
Bloody diarrhoea
427 [86%]
89 [72%]
Abdominal pain
409 [82%]
99 [80%]
Isolated abdominal pain
4 [1%]
2 [2%]
Fever
41 [3%]
4 [4%]
Vomiting
73 [18%]
15 [15%]
Skin manifestations
14 [3%]
5 [5%]
Oral ulcers
40 [10%]
12 [12%]
Arthritis
7 [2%]
4 [4%]
Anaemia
245 [59%]
56 [57%]
Iron deficiency
220 [53%]
61 [62%]
Extraluminal manifestations at presentation [as per physician assessment]
Any extraintestinal manifestation
42 [9%]
13 [12%]
Skin involvement
4 [0.9%]
0
Joint involvement
10 [2%]
4 [4%]
Anthropometrics at presentation
Height for age z-score
0.17 [-0.54–0.84]
0.09 [-0.67–0.96]
Weight for age z-score
0.00 [-0.79-0.73]
0.15 [-0.77-0.77]
Reported linear growth impairment
15 [4%]
5 [5%]
Reported weight loss
267 [64%]
45 [46%]
Biochemistry at presentation
CRP [x upper limit of normal]
0.7 [0.2–1.6]
0.6 [0.2–1.2]
ESR [mm/h]
25 [12–42]
18 [10–32]
Albumin [g/L]
38 [33–42]
41 [35–44]
Disease characteristics at presentation
PUCAI
50 [35–65]
40 [25–55]
Physician global assessment
None
17 [4%]
6 [5%]
Mild
111 [23%]
41 [34%]
Moderate
198 [40%]
48 [40%]
Severe
163 [33%]
26 [21%]
Location [Paris classification]
No macroscopic involvement
10 [2%]
4 [4%]
E1 [proctitis]
42 [9%]
15 [13%]
E2 [distal to splenic flexure]
30 [6%]
10 [9%]
E3 [distal to hepatic flexure]
58 [12%]
15 [13%]
E4 [proximal to hepatic flexure]
339 [71%]
69 [61%]
Extensive [E3-E4]
397 [83%]
84 [74%]
Mayo endoscopic subscore
2 [2–3]
2 [1–3]
Medical therapy
Induction
5ASA/sulphasalazine
172 [35%]
61 [49%]
Systemic steroids
300 [60%]
50 [40%]
Anti-TNF
7 [1%]
3 [2%]
Rectal therapy alone
14 [3%]
8 [6%]
None
4 [1%]
2 [2%]

Without diagnostic delay
[N = 377]
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Figure 1. Kaplan‐Meier curve illustrating time to stricturing/internal fistulising complications in Crohn’s disease [CD] patients with inflammatory disease at
presentation by diagnostic delay status [log rank p = 0.001].

Table 3. Association between diagnostic delay and development of stricturing and/or internal fistulising complications among CD patients
with inflammatory disease at presentation.
Factors

Unadjusted hazard ratioa [95% CI]

p-value

Adjusted hazard ratio [95% CI]

p-value

Diagnostic delayb
Male
Age at diagnosis [years]
Small bowel involvementc
Upfront anti-TNF used

2.53 [1.41–4.56]
0.59 [0.33–1.06]
1.11 [0.99–1.24]
4.45 [1.59–12.5]
0.26 [0.06–1.10]

0.002
0.087
0.076
0.004
0.067

2.28 [1.25–4.14]
0.58 [0.32–1.06]
1.07 [0.94–1.20]
4.07 [1.44–11.5]
0.30 [0.07–1.25]

0.007
0.077
0.29
0.008
0.098

CD, Crohn’s disease; HR, hazard ratio; CI, confidence interval; TNF, tumour necrosis factor.
a
HR >1 indicates faster time to diagnosis; HR <1 indicates slower time to diagnosis.
b
Time to diagnosis >75th percentile in CD subgroup [10.8 months].
c
L1, L3 or L4b.
d
As first therapy.

Initial therapy differed by diagnostic delay status, with more exclusive enteral nutrition [EEN] in CD patients with, and more corticosteroids in CD patients without, a delayed diagnosis. EEN was
more frequent in CD patients with small bowel involvement [44%
vs 17%, p <0.001] but the association between diagnostic delay and
EEN persisted in an analysis restricted to patients with small bowel
disease. In UC/IBD-U, diagnostic delay was associated with more
5-aminosalicylic acid [5-ASA] use, whereas patients diagnosed more
rapidly were more likely to receive corticosteroids and anti-tumour
necrosis factor alpha [anti-TNFα].
Baseline patient and disease characteristics are summarised specifically for the IBD-U group in Supplementary Table 1.

3.2. Diagnostic delay in paediatric CD is associated
with a higher rate of stricturing/internal fistulising
complications over time
Of the 803 CD patients with inflammatory disease at presentation,
45 [5.6%] developed stricturing or internal fistulising complications

over time; this included 10% [20/199] of patients with diagnostic
delay compared with 4.1% [25/604] of patients without diagnostic
delay [p = 0.001]. Among those who developed such complications,
the median time to complication was 13 [7–25] months. All CD patients considered, by the end of follow-up, 20% of patients with
diagnostic delay and 12% of those without delay had stricturing/
internal fistulising complications [p = 0.003].
Figure 1 illustrates the faster rate of progression to stricturing/
internal fistulising complications in CD patients with vs without
diagnostic delay [log rank p = 0.001]. Even after adjusting for
small bowel involvement and early anti-TNF use, diagnostic delay
remained significantly associated with a more than 2-fold higher
rate of stricturing/internal fistulising complications over time [HR
2.28, 95% CI 1.25–4.14] [Table 3]. Notably, small bowel involvement was also independently associated with an increased risk of
stricturing/fistulising complications [HR 4.07, 95% CI 1.44–11.5].
Early anti-TNF use was associated with a numerically lower rate
of complications, but this was not statistically significant. A sensitivity analysis restricted to patients with small bowel disease also
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Table 4. Association between time to diagnosis and linear growth [HAZ at presentation] in CD patients.
Factors

Unadjusted beta coefficient
[95% CI]

p-value

Adjusted beta coefficient
[95% CI]

p-value

Symptom duration [months]
Male
Age at diagnosis [years]
Small bowel involvementa

-0.013 [-0.021, -0.005]
-0.075 [-0.237, 0.087]
0.018 [-0.008–0.044]
0.0009 [-0.182–0.184]

0.001
0.36
0.16
0.99

-0.013 [-0.022, -0.005]
-0.058 [-0.223-0.108]
0.020 [-0.007–0.048]
-0.017 [-0.201-0.167]

0.001
0.50
0.14
0.86

HAZ, height for age z-score; CD, Crohn’s disease.
a
L1, L3 or L4b.

Table 5. Association between diagnostic delay and surgery in CD patients.
Unadjusted hazard ratio [95% CI]a

p-value

Adjusted hazard ratio [95% CI]

p-value

Diagnostic delayb
Male
Age at diagnosis [years]
Distal ileal ± caecal [L1]
Upfront anti-TNF use2

1.01 [0.60–1.70]
0.92 [0.59–1.46]
1.04 [0.96–1.12]
1.74 [1.05–2.88]
1.35 [0.77–2.38]

0.97
0.74
0.38
0.032
0.30

0.93 [0.55–1.59]
0.90 [0.57–1.44]
1.02 [0.94–1.11]
1.71 [1.03–2.86]
1.37 [0.77–2.42]

0.80
0.67
0.55
0.040
0.28

CD, Crohn’s disease; TNF, tumour necrosis factor; CI, confidence nterval; HR, hazard ratio.
a
HR >1 indicates faster time to diagnosis; HR <1 indicates slower time to diagnosis.
b
Time to diagnosis >75th percentile in CD subgroup [10.8 months].
c
As first therapy.

yielded significant findings for diagnostic delay [HR 2.00, 95% CI
1.06–3.78] [Supplementary Table 2, available as Supplementary data
at ECCO-JCC online].

3.3. Diagnostic delay in paediatric CD is associated
with linear growth impairment at presentation
Table 4 shows the results of univariate and MVA linear regression
examining the association between time to diagnosis and HAZ at
presentation. After adjusting for patient demographics [age, sex]
and small bowel involvement, a longer time to diagnosis remained
significantly associated with lower HAZ [beta coefficient -0.013,
95% CI -0.022 to -0.005]. In other words, for every additional
month of symptoms before diagnosis, HAZ decreased by 0.013
standard deviations. This association was preserved in a sensitivity
analysis restricted to CD patients with small bowel involvement
[Supplementary Table 3, available as Supplementary data at ECCOJCC online].

3.4. Diagnostic delay is not associated with an
increased risk of surgery in paediatric CD or UC/
IBD-U
By the end of follow-up, 107 patients [7.1% overall] underwent surgery (76 CD [8.5% of the total CD cohort] and 31 UC/IBD-U [6.2%
of the total UC/IBD-U cohort]). In CD, surgery occurred in the same
proportion of patients with and without diagnostic delay [8%]. In
UC/IBD-U, surgery was in fact more common in patients without
diagnostic delay [7% compared with 2%, p = 0.048]. However, in
adjusted analyses controlling for patient age, sex, and disease location [L1 vs other for CD, and pancolitis vs less extensive disease for
UC/IBD-U], diagnostic delay was not independently associated with
risk of surgery over time in either CD [HR 0.93, 95% CI 0.55–1.59]
or UC/IBD-U [HR 0.41, 95% CI 0.12–1.34] [Tables 5 and 6, respectively]. This was also the case in an analysis restricted to CD patients with inflammatory disease at presentation and in a UC/IBD-U
sensitivity analysis excluding patients presenting with severe colitis

[PUCAI ≥65]. In CD, L1 location was independently associated
with an increased risk of surgery [HR 1.71, 95% CI 1.03–2.86]. As
shown in Supplementary Table 5, available as Supplementary data
at ECCO-JCC online, diagnostic delay was not associated with an
increased risk of surgery in the IBD-U group either.

3.5. Predictors of time to diagnosis in
paediatric IBD
Last, we sought to identify predictors of time to diagnosis known
at presentation [ie, before diagnostic endoscopy]. This analysis
was therefore undertaken for the entire IBD cohort as a whole.
Variables were selected for inclusion in the MVA model based on
clinical relevance. As shown in Supplementary Table 4, available
as Supplementary data at ECCO-JCC online, abdominal pain,
iron deficiency, and linear growth impairment were independently
associated with a longer time to diagnosis, and bloody diarrhoea,
vomiting, and constitutional symptoms, such as fever and weight
loss, were associated with a shorter time to diagnosis. More severe
clinical activity was also associated with a shorter time to diagnosis.
Of note, these associations remained significant when IBD type was
added to the model.

4. Discussion
This is the largest study to date to examine the association between
diagnostic delay and disease complications in paediatric IBD and
the first paediatric study, to our knowledge, to report that diagnostic delay is independently associated with an increased risk of
stricturing/internal fistulising complications over time in CD. We
also observed an independent association between diagnostic delay
and lower height in CD. We found no independent link, however,
between diagnostic delay and risk of surgery in either CD or UC/
IBD-U. In addition, we identified several patient and disease factors
associated with diagnostic delay. CD was associated with a longer
time to diagnosis than UC/IBD-U. In the CD subgroup, those with
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Table 6. Association between diagnostic delay and surgery in UC/IBD-U patients.
Factorsa

Unadjusted hazard ratio [95% CI]c

p-value

Adjusted hazard ratio [95% CI]

p-value

Diagnostic delayb
Male
Age at diagnosis [years]
Pancolitis [E4]

0.35 [0.11–1.16]
1.70 [0.81–3.55]
1.01 [0.91–1.12]
2.26 [0.87–5.90]

0.085
0.16
0.85
0.094

0.41 [0.12–1.34]
1.70 [0.81–3.55]
1.02 [0.92–1.12]
2.14 [0.82–5.58]

0.14
0.16
0.78
0.12

UC/IBDU, ulcerative colitis/inflammatory boweldisease unclassified; TNF, tumour necrosis factor; CI, confidence nterval; HR, hazard ratio.
a
Anti-tumour necrosis factor-alpha [anti-TNF] use not included in model as virtually all UC/IBD-U patients who underwent surgery were first treated with
anti-TNF [positioning anti-TNF use in the causal pathway].
b
Time to diagnosis >75th percentile in UC/IBD-U subgroup [6.6 months].
c
HR >1 indicates faster time to diagnosis; HR <1 indicates slower time to diagnosis.

between the increased risk of stricturing/internal fistulising complications, but not surgery, in CD patients with diagnostic delay may
relate to the potentially prolonged interval between radiographic/
clinical diagnosis of stricturing/fistulising complications and surgical intervention, as well as our relatively short follow-up duration.
However, this discordance might also relate to the early use of effective biologic agents. More generally, the frequently early use of
biologics for paediatric IBD in the current era may also account for
the fact that paediatric studies, thus far, have not supported an increased risk of surgery with diagnostic delay in CD, as has been the
case in the adult literature. We did not find that diagnostic delay
was associated with an increased risk of colectomy in UC/IBD-U either; in fact, in univariate analyses, colectomy was more frequent in
patients without diagnostic delay. This may reflect the predilection
of this group for more anatomically extensive and severe disease,
as shown in Table 2. These findings are in keeping with those of a
retrospective paediatric UC study, in which median time to diagnosis
was shorter in patients who underwent colectomy compared with
those who did not.23
In keeping with a number of earlier paediatric studies,14,24–27
we confirmed the association between diagnostic delay and linear
growth impairment in paediatric CD. Notably, we showed that this
association was not merely the result of the confounding effect of
disease location; the association between diagnostic delay and lower
HAZ was preserved in adjusted and sensitivity analyses controlling
for small bowel involvement.
Table 7 summarises time to diagnosis in CD and UC in adult and
paediatric studies; this illustrates that our findings are generally in
keeping with previous paediatric studies, and that time to diagnosis
tends to be longer in adults than in children. In addition, it demonstrates that CD, especially small bowel CD, is consistently associated
with a longer time to diagnosis than UC, in both adults7,9,15,20,21,28,29
and children.12,14,24,25,27,30 We also found CD and isolated small bowel
disease to be associated with diagnostic delay. This may well relate
to the less frequent occurrence of overt intestinal symptoms, such
as bloody diarrhoea, in the setting of small bowel CD. As shown
in Table 7, the association between age and diagnostic delay has
been conflicting in adult studies, but several paediatric studies have
suggested that younger children are at increased risk of diagnostic
delay.12,25,27,31 The absence of this finding in our cohort may reflect
the decreasing age of IBD onset in Canada and thus greater awareness of IBD even in the youngest of children. In keeping with our
findings, previous paediatric studies have suggested that symptoms
other than diarrhoea are associated with diagnostic delay,25 whereas
haematochezia is protective against diagnostic delay.25 A small
number of studies have also reported an association between perianal symptoms/disease and diagnostic delay.17,25 Although we
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isolated small bowel disease were particularly at risk; in the UC/
IBD-U subgroup, those with less extensive disease more often had
diagnostic delay. Factors reflecting more severe disease activity,
clinically, endoscopically, or biochemically, were associated with a
shorter time to diagnosis. Among factors known at time of presentation, abdominal pain and linear growth impairment were associated with diagnostic delay, whereas intestinal and extraintestinal
symptoms, such as bloody diarrhoea, fever, and weight loss, were
associated with a faster diagnosis. This is likely due to their prompt
recognition as worrisome by patients, caregivers, and referring
physicians. Abdominal pain, particularly in isolation, is a relatively
common and non-specific symptom, which may be attributed to
functional aetiologies or organic entities besides IBD. This highlights
the need for greater education about the possibility of new-onset
IBD presenting in this subtle manner in children and the utility of
objective biomarkers like faecal calprotectin in this setting. In an
earlier study, we demonstrated that the biggest contributor to time to
diagnosis is the interval between symptom onset and time of referral
to a paediatric gastroenterologist.14 This suggests that educational
interventions are best targeted at primary care physicians, including
family doctors and general paediatricians.
Table 7 summarises adult and paediatric studies on diagnostic
delay in IBD published over the past 20 years. As illustrated, numerous adult studies support an association between diagnostic
delay and IBD complications, particularly bowel stenosis, internal
fistulae, and surgical resection,5–9,13,15–21 as well as perianal fistulising
disease,8 biologic use,21,22 and impaired quality of life.19 Conversely,
paediatric data on the relationship between diagnostic delay and
IBD complications are scant. Our findings are congruent with the
adult literature; in our cohort, paediatric CD patients with diagnostic delay experienced stricturing/internal fistulising complications subsequent to diagnosis more than twice as often as children
without diagnostic delay. Importantly, this association persisted
after accounting for small bowel involvement and anti-TNF use. The
Swiss IBD Cohort Study also recently investigated this association in
a paediatric population. In examining 387 paediatric CD patients,
Schoepfer et al. found that children with diagnostic delay were less
likely to have disease complications at diagnosis, and no significant
association was observed between diagnostic delay and the risk of
complications over time.8 In contrast, we purposefully restricted
our analysis to patients with inflammatory CD at presentation, to
examine the influence of diagnostic delay on the subsequent risk of
developing complications [rather than the effect of complications on
presenting symptoms]. This factor, as well as our larger sample size,
might account for our differing findings.
As in the Swiss IBD Cohort Study, we found no association between diagnostic delay and surgery in CD. The apparent disconnect

Li [2015]13
China

Retrospective
registry-based,
multicentre
Retrospective chart
review, single centre

Moon [2015]18
South Korea
343 CD

1047 CD

10 [2–34]

Mean 16
[±33.1]

11 [1–163]

1

5

361 CD

2.0 [0–7]

7.1 [1–26]

5 [2–13]

2.4

3.1 [1–10]

55

2.3 [?-6.4]

3 [1–10]

Ulcerative
colitis [UC]

6.2

9.5 [4–26]

18 [28–30]

25

6 [2–23]

6 [1–24]

Crohn’s
disease [CD]

3.0 [0–13]

Overall

Time to diagnosis [months, median [IQR]
unless otherwise specified]

497 CD

478 CD
682 UC
36 IBD-U

National registrybased, multicentre

Prospective database, multicentre
Cross-sectional,
single centre

165 CD
130 UC
1537 CD
1855 UC

110 CD
67 UC

428 CD
483 UC
720 CD

830 CD
435 UC
21 IBD-U
551 UC

1163 CD

N
IBD type

Retrospective chart
review, single centre
Prospective registrybased, multicentre

Retrospective chart
review, multicentre
Prospective registrybased, single centre
Retrospective analysis of prospective
registry, single centre
Retrospective chart
review, single centre

Cross-sectional,
multicentre

National cohort
study, prospective
2006 onward,
retrospective prior
to 2005

Nahon [2016]6
France
Pellino [2015]19
Italy

Lee [2017]17
South Korea
Cantoro
[2017]15
Italy
Zaharie
[2016]9
Romania

Novacek
[2019]28
Austria
Kang [2019]22
South Korea
Szanto [2018]21
Hungary
Banerjee
[2018]5
India
Nguyen
[2017]7
USA

Adult
Schoepfer
[2019]8
Switzerland

Study design

Age >40 y, education level, no family history
of CD

Age >40 y, upper gastrointestinal tract disease

CD [vs UC]
Ileal location, active smoking, symptom
onset during summer [in CD]
Age <40 y [in UC]

CD [vs UC], age >40 y

CD [vs UC]
Exclusive ileal location [in CD]
Haematochezia associated with faster diagnosis [in CD]
Perianal discomfort [in CD]

Age <60 y, smoking, misdiagnosis of haemorrhoids
CD [vs UC]

CD [vs UC], older age, higher level education

Predictors of diagnostic delay

Yes—diagnostic delay associated with surgery

Yes—diagnostic delay >13 months associated with
shorter time to first major surgery
Yes—diagnostic delay >18 months associated with
poorer quality of life, risk of surgery and penetrating disease at presentation
Yes—diagnostic delay >18 months associated with
penetrating disease at presentation

Yes—diagnostic delay associated with bowel stenosis and IBD-related surgery

Yes—diagnostic delay associated with intestinal
surgery in CD and UC
Yes—diagnostic delay >24 months associated with
complicated disease at CD diagnosis

Yes—diagnostic delay >26 months associated with
increased overall complications and intestinal strictures in CD

Yes—diagnostic delay >24 months associated with
anti-tumour necrosis factor-alpha use
Yes—diagnostic delay >1 y associated with surgery
and biologic use [in CD and UC]
Yes—diagnostic delay >12 and >18 months associated with stenosis and surgery

Yes, diagnostic delay associated with a higher rate
of stenosis, perianal fistulae, internal fistulae, any
fistulae, surgical resection, fistula surgery at presentation; diagnostic delay associated with stenosis
internal fistulae and any complication over time
after diagnosis

Diagnostic delay identified as a risk factor for disease complications?
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National cohort
study, prospective
2006 onward,
retrospective prior
to 2005

Schoepfer
[2017]32
Switzerland

Ricciuto
[2018]14
Canada

Retrospective chart
review [2003–2012],
prospective [2011–
2018], multicentre
Prospective cohort
study, single centre

National cohort
study, prospective
2006 onward,
retrospective prior
to 2005
Retrospective chart
review, single centre

El Mouzan
[2019]12
Saudi Arabia

Krishna [2019]
USA23

Paediatric
Schoepfer
[2019]8
Switzerland

100 CD
75 UC

65 CD
46 UC/
IBD-U

240 CD
183 UC

106 UC

387 CD

932 CD
625 UC
34 IBD-U

223 CD

905 CD

National cohort
study, prospective
2006 onward,
retrospective prior
to 2005
Retrospective chart
review, single centre
National cohort
study, prospective
2006 onward,
retrospective prior
to 2005

Schoepfer
[2013]20
Switzerland

4 [2–8]

6.8
[2.9–12.5]

8 [4–24]

3 [1–9]

24 [range
6–240]
9 [3–24]

9 [3–24]

Crohn’s
disease [CD]

2 [1–7]

2.4 [1.3–5.3]

7.1 [3.2–
21.5] wk
[colectomy]
11.9 [5.9–
25.7] wk [no
colectomy]
5 [2.1–8.8]

4 [1–12]

Ulcerative
colitis [UC]

4.5
[2.1–8.8]

Overall

Time to diagnosis [months, median [IQR]
unless otherwise specified]

CD, small bowel disease
Diarrhoea, blood per rectum, weight loss associated with faster diagnosis in unadjusted
analysis
None identified

CD
Ileal location [in CD]
<10 years at diagnosis [in UC]

Age <40 y, ileal location [in CD]
NSAID use, male [in UC]

Female, ileal location, age ≥40 y at diagnosis

Predictors of diagnostic delay

Yes—lower height for age z-score

No—diagnostic delay associated with a lower risk
of stricture, internal fistulae. and surgery at diagnosis; no significant association between diagnostic
delay and disease complications over time following
diagnosis
No—time to diagnosis shorter in patients who
underwent colectomy

Yes—diagnostic delay associated with complicated
disease behaviour over time

Yes –diagnostic delay associated with bowel stenosis and intestinal surgery

Diagnostic delay identified as a risk factor for disease complications?
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N
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Mean 3

4.6 [0.5–36]

Mean 6.7

10.8 [range
0.9–84]
Mean 7.1

4.8 [2.4–8.4]

Mean 4.5

6 [3.6–12]

5 [range
<1 mo-9
y]

Small bowel [in CD]

Symptoms other than diarrhoea

Yes—growth failure

Yes—growth impairment
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IBDU, inflammatory bowel disease unclassified; CD, Crohn’s disease; UC, ulcerative colitis; IQR, interquartile range; y, year; mo, month; wk, week.

Retrospective chart
review, single centre

Heineken
[1999]24
USA

129 CD
60 UC
10 IBD-U
64 CD
41 UC
7 IBD-U
58 CD
24 UC
9 IBD-U

CD [vs UC], young age
Oral, perianal, jejunal [in CD]
Rectal bleeding associated with faster diagnosis
CD [vs UC]

431 CD
211 UC
86 IBD-U

Survey, multicentre

Prospective registry
[voluntary reporting]
Retrospective chart
review, single centre

Yes—short stature

CD [vs UC], young age [<6 y]
Centre effect
Ileal location [in CD]

4 [2–8]

1456 CD
817 UC
163 IBD-U

Registry-based, prospective and retrospective, multicentre

Kugathasan
[2003]30
USA
Spray [2001]26
UK

Yes—growth failure

CD [vs UC], young age [trend only for both]

2.8
[1.1–5.5]

3.6 [9.6]
<10 y
3.6 [4.8]
≥10 y

6.0 [9.6]
<10 y
6.0 [8.4]
≥10 y

Overall

31 CD
19 UC
3 IBD-U

Ulcerative
colitis [UC]

Crohn’s
disease [CD]

Retrospective chart
review, single centre

Diagnostic delay identified as a risk factor for disease complications?

616 CD
278 UC
64 IBD-U

Predictors of diagnostic delay

Registry-based, prospective and retrospective, multicentre

Time to diagnosis [months, median [IQR]
unless otherwise specified]

Buderus
[2015]33
Germany &
Austria
ArcosMachancoses
[2014]31
Spain
Timmer
[2011]27
Germany &
Austria
Sawczenko
[2003]25
UK

N
IBD type

Study design

Author [year]
Country

Table 7. Continued

Diagnostic Delay in Paediatric IBD
429

A. Ricciuto et al.

430

Funding
This work was supported by grant 297862 from the Canadian Institutes of
Health Research [CIHR] in partnership with the Children’s Intestinal and Liver
Disease [Ch.I.L.D.] Foundation. EIB was supported by a New Investigator
Award from the Canadian Institutes of Health Research, Canadian Association
of Gastroenterology, and Crohn’s and Colitis Canada. EIB was also supported
by the Career Enhancement Program of the Canadian Child Health Clinician
Scientist Program.

Potential competing interests
HH—advisory board: AbbVie, Janssen, Merck; research support: Janssen. KJ—
advisory board: AbbVie, Janssen, Merck; speaker’s bureau: AbbVie Janssen;
investigator-initiated research support: Janssen. AO—advisory board: AbbVie,
Janssen, Shire; consultant: AbbVie, Janssen, Lilly; research site: AbbVie,
Janssen, Takeda. JdB—advisory board: AbbVie, Janssen, Merck. WE-M—advisory board: AbbVie, Janssen, Merck. CD—advisory board: AbbVie, Janssen,

Merck. MS—advisory board: AbbVie, Merck. KB—advisory board: AbbVie,
Mead Johnson; pharmaceutical trials: AbbVie, Takeda, Janssen, Allergan,
Pfizer; speaker: Mead Johnson; unrestricted educational grant: AbbVie.
PJ—consultant: AbbVie, Janssen; advisory board: Ferring. EW—consultant:
AbbVie, Janssen. MC—advisory board: AbbVie, Janssen. SL—advisory board:
Janssen; speaker: AbbVie. JL—consulting, travel, and/or speaker fees and research support: AbbVie, Janssen, Nestlé Health Science, Merck, P&G, GSK,
Illumina, Otsuka. TW—consultant: AbbVie, Ferring, Janssen, Merck; speaker:
AbbVie, Ferring, Janssen, Merck, Nestle. AG—consultant: AbbVie, Merck,
Janssen, Eli Lilly, Pfizer, Gilead, Roche, Takeda; speaker: AbbVie, Janssen,
Shire; investigator-initiated research support: AbbVie. PC—consultant:
AbbVie, Ferring, Janssen, Merck; speaker: AbbVie; research support: AbbVie.

Author Contributions
All authors contributed to acquisition of data, critical revision of the manuscript for important intellectual content, and approval of the final manuscript
as submitted. PC, AG, TW, and AR contributed to the study concept and design, analysis and interpretation of data, statistical analysis, and drafting of the
manuscript; PC provided study supervision.
The contents of this article were presented at the NASPGHAN Annual
Meeting in Fort Lauderdale, USA, in 2018.

Acknowledgements
We acknowledge the assistance of Sophie Rossini with data extraction.

Supplementary Data
Supplementary data are available at ECCO-JCC online.

References
1. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of
inflammatory bowel disease in the 21st century: a systematic review of
population-based studies. Lancet 2018;390:2769–78.
2. Coward S, Clement F, Benchimol EI, et al. Past and future burden of inflammatory bowel diseases based on modeling of population-based data.
Gastroenterology 2019;156:1345–1353.e4.
3. Benchimol EI, Fortinsky KJ, Gozdyra P, Van den Heuvel M,
Van Limbergen J, Griffiths AM. Epidemiology of pediatric inflammatory
bowel disease: a systematic review of international trends. Inflamm Bowel
Dis 2011;17:423–39.
4. Vadstrup K, Alulis S, Borsi A, et al. Cost burden of Crohn’s disease and ulcerative colitis in the 10-year period before diagnosis ‐ a Danish register-based
study from 2003–2015. Inflamm Bowel Dis 2019. doi: 10.1093/ibd/izz265
5. Banerjee R, Pal P, Girish BG, Reddy DN. Risk factors for diagnostic delay
in Crohn’s disease and their impact on long-term complications: how do
they differ in a tuberculosis endemic region? Aliment Pharmacol Ther
2018;47:1367–74.
6. Nahon S, Lahmek P, Paupard T, et al. Diagnostic delay is associated with a
greater risk of early surgery in a French cohort of Crohn’s disease patients.
Dig Dis Sci 2016;61:3278–84.
7. Nguyen VQ, Jiang D, Hoffman SN, et al. Impact of diagnostic delay and
associated factors on clinical outcomes in a U.S. inflammatory bowel disease cohort. Inflamm Bowel Dis 2017;23:1825–31.
8. Schoepfer A, Santos J, Fournier N, et al. Systematic analysis of the impact of diagnostic delay on bowel damage in paediatric versus adult onset
Crohn’s disease. J Crohns Colitis 2019;13:1334–42.
9. Zaharie R, Tantau A, Zaharie F, et al.; IBDPROSPECT Study Group.
Diagnostic delay in Romanian patients with inflammatory bowel disease: risk factors and impact on the disease course and need for surgery. J
Crohns Colitis 2016;10:306–14.
10. Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the
Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011;17:1314–21.

Downloaded from https://academic.oup.com/ecco-jcc/article/15/3/419/5911915 by guest on 23 June 2022

observed a significant relationship between perianal symptoms [as
per patient report] in univariate analyses, this was not maintained
in MVA and was not observed in the CD cohort separately. Perianal
symptoms may therefore simply be associated with diagnostic delay
because they function as a marker of CD.
Our study has numerous strengths. Chief among them are
its large size, prospective nature, and standardised data collection methods. We also used several methods to address potential
confounders, including disease location and medication use. There
are some limitations as well, including the fact that the study is not
truly population-based, as it includes children followed at tertiary
paediatric centres. However, in Canada, it is conventional for paediatric IBD to be managed by paediatric gastroenterologists, the majority of whom practise at academic centres. It will also be important
to undertake studies with longer follow-up duration, to determine
whether the associations noted persist in the longer term. Although
attempts were made in CIDsCaNN to enrol all consecutive paediatric IBD diagnoses over the study period, a small subset declined
participation or were not captured, which may introduce selection
bias; it is, however, reassuring that the full spectrum of disease severity was seen in both the CD and UC/IBD-U cohorts [as reflected
in Tables 1 and 2]. An additional limitation is unavailability of data
on parental social factors [education, income, etc.] and compliance
with medical recommendations, both of which may be confounders
[ie, may be associated with diagnostic delay and adverse outcomes].
We cannot rule this possibility out but, in a previous, smaller study,
we found no association between family income [derived by linking
postal codes to Canadian census data] and diagnostic delay.14 Last,
ascertainment of true symptom onset is challenging and subject to
possible recall bias. In this study, physicians prospectively questioned
patients and parents, at first consultation, about timing of symptom
onset. The prospective nature does not exclude the possibility of recall bias, but it helps to mitigate against it.
In summary, a substantial fraction of children newly diagnosed with IBD in Canada continue to experience prolonged delays between symptom onset and diagnosis. Diagnostic delay is an
important modifiable factor in the management of IBD as it is associated with impaired patient outcomes, including delays in treatment initiation and an increased risk of stricturing/internal fistulising
complications and linear growth impairment in paediatric CD.
Interventions directed at minimising diagnostic delay, such as education about presenting symptoms and signs and improved access to
care, are warranted.

Diagnostic Delay in Paediatric IBD

23. Krishna M, Britto S, Qian J, Ihekweazu F, Rodriguez JR, Kellermayer R.
Diagnostic delay and colectomy risk in pediatric ulcerative colitis. J Pediatr
Surg 2020;55:403–5.
24. Heikenen JB, Werlin SL, Brown CW, Balint JP. Presenting symptoms and
diagnostic lag in children with inflammatory bowel disease. Inflamm
Bowel Dis 1999;5:158–60.
25. Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child
2003;88:995–1000.
26. Spray C, Debelle GD, Murphy MS. Current diagnosis, management
and morbidity in paediatric inflammatory bowel disease. Acta Paediatr
2001;90:400–5.
27. Timmer A, Behrens R, Buderus S, et al.; CEDATA-GPGE Study Group.
Childhood onset inflammatory bowel disease: predictors of delayed diagnosis from the CEDATA German-language pediatric inflammatory bowel
disease registry. J Pediatr 2011;158:467–73.e2.
28. Novacek G, Gröchenig HP, Haas T, et al.; Austrian IBD Study Group
[ATISG]. Diagnostic delay in patients with inflammatory bowel disease in
Austria. Wien Klin Wochenschr 2019;131:104–12.
29. Vavricka SR, Spigaglia SM, Rogler G, et al.; Swiss IBD Cohort Study
Group. Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis 2012;18:496–505.
30. Kugathasan S, Judd RH, Hoffmann RG, et al.; Wisconsin Pediatric
Inflammatory Bowel Disease Alliance. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr
2003;143:525–31.
31. Arcos-Machancoses JV, Donat-Aliaga E, Polo-Miquel B, Masip-Simó E,
Ribes-Koninckx C, Pereda-Pérez A. [Description and study of risk factors for the diagnostic delay of pediatric inflammatory bowel disease]. An
Pediatr [Barc] 2015;82:247–54.
32. Schoepfer AM, Vavricka S, Safroneeva E, et al. Systematic evaluation
of diagnostic delay in pediatric inflammatory bowel disease. J Pediatr
Gastroenterol Nutr 2017;64:245–7.
33. Buderus S, Scholz D, Behrens R, et al.; CEDATA-GPGE Study Group.
Inflammatory bowel disease in pediatric patients: characteristics of newly
diagnosed patients from the CEDATA-GPGE Registry. Dtsch Arztebl Int
2015;112:121–7.

Downloaded from https://academic.oup.com/ecco-jcc/article/15/3/419/5911915 by guest on 23 June 2022

11. Dhaliwal J, Walters TD, Mack DR, et al. Phenotypic variation in paediatric
inflammatory bowel disease by age: a multicentre prospective inception cohort
study of the Canadian children IBD network. J Crohns Colitis 2020;14:445–54.
12. El Mouzan MI, AlSaleem BI, Hasosah MY, et al. Diagnostic delay of pediatric inflammatory bowel disease in Saudi Arabia. Saudi J Gastroenterol
2019;25:257–61.
13. Li Y, Ren J, Wang G, et al. Diagnostic delay in Crohn’s disease is associated
with increased rate of abdominal surgery: a retrospective study in Chinese
patients. Dig Liver Dis 2015;47:544–8.
14. Ricciuto A, Fish JR, Tomalty DE, et al. Diagnostic delay in Canadian children with inflammatory bowel disease is more common in Crohn’s disease
and associated with decreased height. Arch Dis Child 2018;103:319–26.
15. Cantoro L, Di Sabatino A, Papi C, et al. The time course of diagnostic
delay in inflammatory bowel disease over the last sixty years: an Italian
multicentre study. J Crohns Colitis 2017;11:975–80.
16. Goel A, Dutta AK, Pulimood AB, Eapen A, Chacko A. Clinical profile and
predictors of disease behavior and surgery in Indian patients with Crohn’s
disease. Indian J Gastroenterol 2013;32:184–9.
17. Lee DW, Koo JS, Choe JW, et al. Diagnostic delay in inflammatory bowel
disease increases the risk of intestinal surgery. World J Gastroenterol
2017;23:6474–81.
18. Moon CM, Jung SA, Kim SE, et al.; CONNECT study group. Clinical factors and disease course related to diagnostic delay in Korean Crohn’s disease
patients: results from the CONNECT study. PLoS One 2015;10:e0144390.
19. Pellino G, Sciaudone G, Selvaggi F, Riegler G. Delayed diagnosis is influenced by the clinical pattern of Crohn’s disease and affects treatment outcomes and quality of life in the long term: a cross-sectional study of 361
patients in Southern Italy. Eur J Gastroenterol Hepatol 2015;27:175–81.
20. Schoepfer AM, Dehlavi MA, Fournier N, et al.; IBD Cohort Study
Group. Diagnostic delay in Crohn’s disease is associated with a complicated disease course and increased operation rate. Am J Gastroenterol
2013;108:1744–53; quiz 1754.
21. Szántó K, Nyári T, Bálint A, et al. Biological therapy and surgery rates in
inflammatory bowel diseases ‐ data analysis of almost 1000 patients from
a Hungarian tertiary IBD center. PLoS One 2018;13:e0200824.
22. Kang HS, Koo JS, Lee KM, et al. Two-year delay in ulcerative colitis diagnosis is associated with anti-tumor necrosis factor alpha use. World J
Gastroenterol 2019;25:989–1001.

431

